You searched for - Page 6 of 8 - Fennec Pharmaceuticals : Fennec Pharmaceuticals

Fennec Announces Presentation of Positive Interim Sodium Thiosulfate Phase III Safety Data at the 2015 ASCO Annual Meeting

Posted on May 31, 2015 by cmdsonline

RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwired – May 31, 2015) – Fennec Pharmaceuticals, Inc. (TSX:FRX) (OTCQB:FENCF), announced the presentation of positive interim results from a poster presented today entitled, “Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) […]

FENNEC TO PRESENT AT THE JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE

Posted on May 29, 2015 by cmdsonline

Research Triangle Park, NC, May 29, 2015 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), today announced that it will present at the Jefferies 2015 Global Healthcare Conference being held in New York City. Rosty Raykov, CEO, will provide an overview of the Company’s business on Tuesday, June 2, 2015 at 11:30 a.m. (ET). The […]

Fennec Announces Results of Annual Meeting

Posted on May 29, 2015 by cmdsonline

Research Triangle Park, NC — (Marketwired) – May 28, 2015 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF) today announced that the nominees listed in the management proxy circular dated April 23, 2015 (the “Circular”) for the Annual Meeting of Shareholders were elected as directors of the Company at the Annual Meeting of Shareholders held […]

FENNEC PROVIDES CORPORATE UPDATE AND FIRST QUARTER ENDED MARCH 31, 2015 FINANCIAL RESULTS

Posted on May 15, 2015 by cmdsonline

SIOPEL 6 Safety Data Featured in Poster at ASCO 2015 Strengthening of financial position through warrant proceeds Presenting at Jefferies 2015 Global Healthcare Conference Research Triangle Park, NC, May 15, 2015 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of […]

FENNEC ANNOUNCES AVAILABILITY OF SIOPEL 6 STUDY ABSTRACT FOR ASCO 2015 MEETING

Posted on May 14, 2015 by cmdsonline

End of treatment anti-tumor efficacy in Standard Risk Hepatoblastoma patients shows no adverse outcome related to Sodium Thiosulfate Research Triangle Park, NC, May 14, 2015 – Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), today announced that sodium thiosulfate (STS) will be featured in the abstract titled “Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised […]

FENNEC PHARMACEUTICALS ANNOUNCES THE EXERCISE OF WARRANTS BY THE COMPANY’S LARGEST SHAREHOLDER AND PROVIDES UPDATED CORPORATE CAPITAL STRUCTURE

Posted on May 4, 2015 by cmdsonline

Fennec receives net proceeds of $0.45 million from the exercise of warrants Research Triangle Park, NC, May 4, 2015 – Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), today reported that Southpoint Master Fund, LP (“Southpoint”), the Company’s largest shareholder with 36.6% of Fennec’s issued and outstanding shares has exercised 0.3 million warrants at a price […]

FENNEC PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND FISCAL YEAR ENDED DECEMBER 31, 2014 FINANCIAL RESULTS

Posted on April 1, 2015 by cmdsonline

SIOPEL 6 SAFETY DATA UPDATE SUBMITTED TO ASCO 2015 RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwired – April 1, 2015) – Fennec Pharmaceuticals Inc. (FRX.TO)(FENCF), a clinical stage biopharmaceutical company focused on the development of sodium thiosulfate (STS) for the prevention of ototoxicity from cisplatin in pediatric patients, today reported its corporate update and financial results for the […]

FENNEC PHARMACEUTICALS ANNOUNCES THAT THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC) RECOMMENDS THE CONTINUATION OF SIOPEL 6 PHASE 3 CLINICAL TRIAL

Posted on February 2, 2015 by cmdsonline

Positive recommendation after final safety review of 100 Patients Research Triangle Park, NC, February 2, 2015 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a company focused on the development of sodium thiosulfate (STS) for the prevention of ototoxicity from cisplatin in pediatric patients, announced that the IDMC overseeing the SIOPEL 6 phase 3 clinical […]

FENNEC PHARMACEUTICALS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN SODIUM THIOSULFATE PHASE 3 SIOPEL 6 STUDY

Posted on January 5, 2015 by cmdsonline

116 total patients enrolled Independent safety data review of first 100 patients expected Q1 2015 Research Triangle Park, NC, January 5, 2015 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), today reported the second sodium thiosulfate Phase 3 study, conducted by the International Childhood Liver Tumour Strategy Group, SIOPEL 6, has fully enrolled and is […]

FENNEC ANNOUNCES PRIVATE PLACEMENT OF UNITS

Posted on December 3, 2014 by cmdsonline

Research Triangle Park, NC, December 3, 2014 – – Fennec Pharmaceuticals Inc. (the “Company” or “Fennec”) (TSX: FRX, OTCQB: FENCF), announced today that it has completed a non-brokered private placement (the “Offering”) of 732,266 units for gross proceeds of US$2,196,798. Each unit (a “Unit”) was issued at a price of US$3.00 per Unit and consists […]